Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 11/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | HBB | P68871 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22956572 | 0.88 | MCHR1 (0.42) | ATF4MCHR1MAPK1HBBSYK | |
| SCHEMBL22627900 | 0.85 | OPRK1 (0.44) | ATF4 | |
| SCHEMBL22956555 | 0.82 | ATF4 (0.51) | ATF4MCHR1 | |
| SCHEMBL22627787 | 0.81 | MCHR1 (0.44) | ATF4MCHR1MAPK1HBBSYK | |
| SCHEMBL22628461 | 0.81 | RXFP1 (0.40) | ATF4HPGD | |
| SCHEMBL22627585 | 0.80 | RXFP1 (0.54) | ATF4HTT | |
| SCHEMBL22956444 | 0.79 | OPRK1 (0.43) | ATF4 | |
| SCHEMBL25797236 | 0.79 | ALDH1A1 (0.44) | ATF4HPGD | |
| SCHEMBL22627915 | 0.78 | ALDH1A1 (0.43) | ATF4 | |
| SCHEMBL22628057 | 0.78 | ATF4 (0.46) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452456-B1 | BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-10913727-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913727-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | ATF4 1/4885MCHR1 2867/4885MAPK1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.